Want to see NTRA full AI Analyst Report?
NTRA Stock Chart & Stats
$261.99
-$0.15(-0.06%)
At close: 4:00 PM EDT
$261.99
-$0.15(-0.06%)
Day’s Range― - ―
52-Week Range$131.81 - $288.04
Previous CloseN/A
Volume87.41K
Average Volume (3M)1.44M
Market Cap
$38.35B
Enterprise Value$27.45K
Total Cash (Recent Filing)$1.09B
Total Debt (Recent Filing)$240.08M
Price to Earnings (P/E)―
Beta0.89
Next Earnings
Aug 06, 2026EPS Estimate
-0.49Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.63
Shares Outstanding143,215,380
10 Day Avg. Volume924,721
30 Day Avg. Volume1,435,349
Financial Highlights & Ratios
PEG Ratio230.60
Price to Book (P/B)18.29
Price to Sales (P/S)13.58
P/FCF Ratio287.05
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$285.56Price Target Upside9.00% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering19
EPS Forecast (FY)-1.62
Revenue Forecast (FY)$2.80B
Bulls Say, Bears Say
Bulls Say
Solid Balance Sheet And Low LeverageLow leverage and modest absolute debt provide financial flexibility to fund continued scaling, trials, and commercialization without near-term refinancing risk. This supports multi-quarter durability through reimbursement cycles and enables strategic investments while preserving liquidity.
Improving Cash Generation And Positive Free Cash FlowConsistent positive operating and free cash flow signals that the business is converting growth into internally generated capital. That reduces dependence on external funding, funds R&D and trials, and makes investments in commercialization and capacity sustainable over the next several quarters.
Strong Volume Growth, Margin Expansion And Raised GuidanceBroad-based unit growth, rising ASPs and a meaningful guidance raise indicate scalable operations and improving unit economics. Sustained volume and margin expansion strengthen long-term revenue durability and underpin funding for trials and market expansion initiatives.
Bears Say
Ongoing Operating Losses And Negative ReturnsDespite scale and gross margins, persistent negative operating and net results mean the company has not yet demonstrated sustained earnings power. Continued losses can limit free cash flow upside, strain returns metrics, and force trade-offs between profitability and growth over the next several quarters.
Coverage, Prior-authorization And Payer FrictionIncomplete payer coverage and persistent prior-authorization hurdles create structural adoption and collection risks. Even with strong clinical evidence, slow or partial reimbursement expansion can cap addressable market penetration and delay sustainable revenue realization for months to quarters.
Equity Plan Increase Introduces Dilution RiskExpanding the equity award pool supports retention but creates potential dilution for existing shareholders. If equity grants are used to fund growth or replace cash compensation, dilution could meaningfully affect per-share metrics and investor returns during the company’s continued scale-up phase.
Natera News
NTRA FAQ
What was Natera Inc.’s price range in the past 12 months?
Natera Inc. lowest stock price was $131.81 and its highest was $288.04 in the past 12 months.
What is Natera Inc.’s market cap?
Natera Inc.’s market cap is $38.35B.
When is Natera Inc.’s upcoming earnings report date?
Natera Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 4 days.
How were Natera Inc.’s earnings last quarter?
Natera Inc. released its earnings results on May 07, 2026. The company reported -$0.6 earnings per share for the quarter, missing the consensus estimate of -$0.542 by -$0.058.
Is Natera Inc. overvalued?
According to Wall Street analysts Natera Inc.’s price is currently Undervalued.
Does Natera Inc. pay dividends?
Natera Inc. does not currently pay dividends.
What is Natera Inc.’s EPS estimate?
Natera Inc.’s EPS estimate is -0.49.
How many shares outstanding does Natera Inc. have?
Natera Inc. has 143,215,380 shares outstanding.
What happened to Natera Inc.’s price movement after its last earnings report?
Natera Inc. reported an EPS of -$0.6 in its last earnings report, missing expectations of -$0.542. Following the earnings report the stock price went down -11.637%.
Which hedge fund is a major shareholder of Natera Inc.?
Currently, no hedge funds are holding shares in NTRA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Natera Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$285.56 (9.00% Upside)
$285.56 (9.00% Upside)
Blogger Sentiment
Bullish
NTRA Sentiment 70%
Sector Average 65%
Sector Average 65%
Hedge Fund Trend
Decreased
By 450.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $19.6M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 0.8%
Last 30 Days ▲ 2.5%
Last 30 Days ▲ 2.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
85.72%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
50.91%
Trailing 12-Months
Company Description
Natera Inc.
Natera, Inc. is a diagnostics company focused on developing and commercializing a wide array of molecular testing services globally. Its portfolio includes several key offerings: Panorama, a non-invasive prenatal test (NIPT) that screens for chromosomal abnormalities in a fetus using a blood sample from the mother, and also determines zygosity in twin pregnancies. Vistara, designed to identify single-gene disorders by screening for specific single-gene mutations. Horizon, a comprehensive carrier screening test to determine an individual's carrier status for various genetic diseases. Spectrum, utilized during in vitro fertilization (IVF) cycles to detect chromosomal anomalies or inherited genetic conditions. Anora, a miscarriage analysis product that examines fetal chromosomes to help understand the cause of pregnancy loss. Non-invasive paternity testing, which establishes paternity during gestation using blood samples from both the pregnant mother and the alleged father. Beyond reproductive health, Natera also provides specialized tests: Signatera, a sophisticated circulating tumor DNA (ctDNA) technology capable of screening for a generic set of mutations, independent of the individual's specific tumor characteristics. Prospera, a test used to assess and monitor organ transplant rejection. Additionally, the company offers Constellation, a cloud-based software platform that provides laboratory clients with access to Natera's proprietary algorithms and bioinformatics, enabling them to validate and launch their own tests. Natera distributes its products through a direct sales team and an extensive network of approximately 100 laboratory and distribution partners. The company has strategic partnerships, including one with BGI Genomics Co., Ltd. for the development, manufacturing, and commercialization of NGS-based genetic testing assays, and another with Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. Founded in 2003, Natera, Inc. is headquartered in Austin, Texas. It was formerly known as Gene Security Network, Inc. before changing its name in 2012.
NTRA Company Deck
NTRA Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong, broad-based operational momentum—robust revenue and unit growth (Q1 revenue $697M, +39% YoY), record oncology volumes (249k MRD tests, +55% YoY), successful new-product launches (Fetal Focus approaching ~200k annualized orders), improved ASPs (Signatera ~$1,250) and raised guidance (revenue guide midpoint reset up >$120M; gross margin guidance to 65% midpoint). Transient headwinds (work-in-process timing, acquisition-related COGS, temporary DSO impact, weather effects, and some coverage/authorization friction) were identified but characterized as short-term or manageable. Given the magnitude and number of positive operational and financial developments and management's upward guide and investment posture, the highlights materially outweigh the lowlights.View all NTRA earnings summariesNTRA Stock 12 Month Forecast
All Analysts
Top Analysts
Average Price Target
$285.56
▲(9.00% Upside)
Technical Analysis
1 Day
3 Days
1 Week
1 Month
Ownership Overview
3.03% Insiders
34.30% Mutual Funds
2.00% Other Institutional Investors
44.65% Public Companies and
Individual Investors









